OraSure Technologies, Inc.

NASDAQ:OSUR

Medical - Instruments & Supplies

Healthcare
$3.59 -3.47%

-$0.16 today

Market cap
$247.88M
Beta
1.01
P/E (TTM)
-4.0
EPS (TTM)
-$1.08
52W Low $2.08High $4.58

Volume 0.49M

Average 0.61M

OSUR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OraSure Technologies, Inc.NASDAQ: OSUR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $13.31M rose 38.6% year over year, behind the +68.7% change in trailing-twelve-month research & development. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Research & development amounted to 37.0% of revenue in FY2025, up 23.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +38.6% toward the trailing-twelve-month pace of +68.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.31M+16.5% QoQ
Last fiscal yearDec 2025
$42.53M+74.2% YoY
LTMMar 2026
$46.23M+68.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.6%——
1 year+74.2%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
42.53M USD
Year-over-year change
+74.2%
4-year CAGR
+5.6%

Research & Development vs competitors

How OSUR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +68.7% is the 2nd highest of 9, against a peer median of -3.0%.
  • Research & development amounts to 40.9% of revenue for OSUR, versus a peer median of 58.1%.
OSUR Competitors
Research & Development for OSUR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M USD+76.6%+218.7%13864.6%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M USD+41.8%+36.4%—
OSUROraSure Technologies, Inc.LTM Mar 2026$46.23M USD+68.7%+5.5%40.9%
NYXHNyxoah S.A.LTM Mar 2026€42.56M EUR+17.3%+39.2%260.8%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M USD-12.6%+4.1%—
PROFProfound Medical Corp.LTM Mar 2026$21.15M USD-1.0%+12.6%112.1%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M USD-47.4%-11.0%4.2%
PREPrenetics Global LimitedLTM Mar 2026$4.57M USD-56.9%-5.0%4.0%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M USD———
UTMDUtah Medical Products, Inc.LTM Mar 2026$668K USD-5.0%+10.7%1.8%
Peer median (excluding OSUR) —-3.0%+11.6%58.1%

Competitors are the stored peer set for OSUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue233.67M387.48M405.47M185.83M115.02M
Cost of Revenue116.07M239.04M226.05M109.6M66.82M
Gross Profit117.6M148.44M179.42M76.23M48.2M
Gross Margin50.3%38.3%44.2%41.0%41.9%
Research & Development34.17M36.24M33.16M24.42M42.53M
Selling, General & Admin95.08M117.44M92.18M72.41M73.79M
Operating Expenses129.25M153.68M125.34M96.83M116.32M
Depreciation & Amortization11.66M14M19.9M10.87M9.97M
EBITDA2.37M(1.68M)76.16M(6.83M)(56.96M)
EBITDA Margin1.0%-0.4%18.8%-3.7%-49.5%
Operating Income(11.65M)(5.24M)54.08M(20.6M)(68.12M)
Operating Margin-5.0%-1.4%13.3%-11.1%-59.2%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.36M(10.43M)2.18M2.9M1.19M
Income Before Tax(9.29M)(15.68M)56.26M(17.7M)(66.93M)
Pre-Tax Margin-4.0%-4.0%13.9%-9.5%-58.2%
Income Tax Expense13.71M1.46M2.6M1.8M1.8M
Net Income(23M)(17.13M)53.66M(19.5M)(68.73M)
Net Margin-9.8%-4.4%13.2%-10.5%-59.8%
EPS (Basic)(0.32)(0.25)0.73(0.26)(0.94)
EPS (Diluted)(0.32)(0.25)0.72(0.26)(0.94)
Weighted Avg Shares71.98M72.51M73.35M74.43M73.49M
Weighted Avg Shares (Diluted)71.98M72.51M74.39M74.43M73.49M

OraSure Technologies, Inc.

NASDAQ:OSUR

Intrinsic Alpha fair value

Locked

Current Price

$3.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.